Are pathophysiologic reasoning and evidence-based medicine complementary?;Physiopathologie, observations cliniques et essais cliniques randomisés: Quelle complémentarité?

Medecine et Hygiene

Volumn 62, Issue 2506, 2004, Pages 2359-2362

  Aujesky, Drahomir ^a   Cornuz, Jacques ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIOXIDANT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMMUNOSUPPRESSIVE AGENT; MILRINONE; PREDNISONE;

CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; LUNG CARCINOMA; MEDICAL DECISION MAKING; MYOCARDITIS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT MONITORING; PHYSICIAN ATTITUDE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT PLANNING;

EID: 10044249027     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Méthodologie et interprétation des essais thérapeutiques. Disponible à: www.spc.univ-lyon1.fr/polycop/ medecine%29factuelle/chapitre.htm. Accédé le 12.08.2004.
2. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' Guides to the Medical Literature: XXV. Evidence-based medicine: Principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. JAMA 2000; 284: 1290-6.
3. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine. New York: Churchill Livingstone, 1997.
4. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.
5. Guyatt GH, Rennie D. Users' guides to the medical literature: A manual for evidence-based clinical practice. Chicago: AMA Press, 2002.
6. Mason JW, Peters FA. Antiarrhythmic efficacy of encaïnide in patients with refractory recurrent ventricular tachycardia. Circulation 1981; 63: 670-5.
7. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encaïnide, flécaînide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-8.
8. Coltart J, Alderman EL, Robison SC, Harrison DC. Effect of propranolol on left ventricular function, segmental wall motion, and diastolic pressure-volume relation in man. Br Heart J 1975; 37: 357-64.
9. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-91.
10. Timmis AD, Smyth P, Jewitt DE. Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment. Br Heart J 1985; 54: 42-7.
11. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
12. Talwar KK, Goswami KC, Chopra P, et al. Immunosuppressive therapy in inflammatory myocarditis: Long-term follow-up. Int J Cardiol 1992; 34: 157-66.
13. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333: 269-75.
14. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.